418 related articles for article (PubMed ID: 30813468)
21. Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma.
Shah GB; Sharma S; Mehta AA; Goyal RK
J Cardiovasc Pharmacol; 2000 Aug; 36(2):169-75. PubMed ID: 10942157
[TBL] [Abstract][Full Text] [Related]
22. The effect of pneumoperitoneum on intraocular pressure in rabbits with alpha-chymotrypsin-induced glaucoma.
Lentschener C; Leveque JP; Mazoit JX; Benhamou D
Anesth Analg; 1998 Jun; 86(6):1283-8. PubMed ID: 9620521
[TBL] [Abstract][Full Text] [Related]
23. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
[TBL] [Abstract][Full Text] [Related]
24. Treatment of ocular hypertension and glaucoma with dopamine antagonists.
Chiou GC
Ophthalmic Res; 1984; 16(3):129-34. PubMed ID: 6147806
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4.
Williams RD; Cohen JS; Gross RL; Liu CC; Safyan E; Batoosingh AL;
Br J Ophthalmol; 2008 Oct; 92(10):1387-92. PubMed ID: 18621791
[TBL] [Abstract][Full Text] [Related]
26. Topical trans-resveratrol ameliorates steroid-induced anterior and posterior segment changes in rats.
Razali N; Agarwal R; Agarwal P; Tripathy M; Kapitonova MY; Kutty MK; Smirnov A; Khalid Z; Ismail NM
Exp Eye Res; 2016 Feb; 143():9-16. PubMed ID: 26424219
[TBL] [Abstract][Full Text] [Related]
27. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
[TBL] [Abstract][Full Text] [Related]
28. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
29. Intraocular pressure lowering is associated with an increase in the photopic negative response (PhNR) amplitude in glaucoma and ocular hypertensive eyes.
Niyadurupola N; Luu CD; Nguyen DQ; Geddes K; Tan GX; Wong CC; Tran T; Coote MA; Crowston JG
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1913-9. PubMed ID: 23385794
[TBL] [Abstract][Full Text] [Related]
30. Studies of the ocular pulse in primates.
Mittag TW; Serle J; Schumer R; Brodie S; Stegman D; Schmidt KG; Taniguchi T; Rho SH; Podos S
Surv Ophthalmol; 1994 May; 38 Suppl():S183-90. PubMed ID: 7940142
[TBL] [Abstract][Full Text] [Related]
31. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
Curr Eye Res; 2009 Apr; 34(4):282-6. PubMed ID: 19373576
[TBL] [Abstract][Full Text] [Related]
32. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
33. A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.
Prasanna G; Ferrara L; Adams C; Ehara T; Li B; Yang L; Xiang C; Ng CTH; Kim S; Towler C; Topley T; McAllister C; Ghosh M; Newton R; Stacy R; Rice DS; Mogi M
Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1704-1716. PubMed ID: 29610853
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension.
Rauz S; Cheung CM; Wood PJ; Coca-Prados M; Walker EA; Murray PI; Stewart PM
QJM; 2003 Jul; 96(7):481-90. PubMed ID: 12881590
[TBL] [Abstract][Full Text] [Related]
35. Short-term safety of dexamethasone implant for treatment of macular edema due to retinal vein occlusion, in eyes with glaucoma or treated ocular hypertension.
Theodoropoulou S; Ellabban AA; Johnston RL; Cilliers H; Mohamed Q; Sallam AB
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):725-732. PubMed ID: 27878430
[TBL] [Abstract][Full Text] [Related]
36. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model.
Seki M; Tanaka T; Matsuda H; Togano T; Hashimoto K; Ueda J; Fukuchi T; Abe H
Br J Ophthalmol; 2005 Apr; 89(4):504-7. PubMed ID: 15774933
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of the endothelin A (ET
McGrady NR; Minton AZ; Stankowska DL; He S; Jefferies HB; Krishnamoorthy RR
BMC Neurosci; 2017 Mar; 18(1):27. PubMed ID: 28249604
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal non-invasive proton NMR spectroscopy measurement of vitreous lactate in a rabbit model of ocular hypertension.
Ngumah QC; Buchthal SD; Dacheux RF
Exp Eye Res; 2006 Aug; 83(2):390-400. PubMed ID: 16631164
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.
WoldeMussie E; Ruiz G; Wijono M; Wheeler LA
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2849-55. PubMed ID: 11687528
[TBL] [Abstract][Full Text] [Related]
40. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.
Bengtsson B; Leske MC; Hyman L; Heijl A;
Ophthalmology; 2007 Feb; 114(2):205-9. PubMed ID: 17097736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
